Brief: Xspray Pharma, Bristol Myers Squibb Reach Settlement On Dasynoc Patent Litigation

Xspray Pharma publ AB

11/09/2023 15:51

Sept 11 (Reuters) - Xspray Pharma Ab (Publ)  XSPAY.ST :
    * XSPRAY PHARMA AND BRISTOL MYERS SQUIBB REACH SETTLEMENT ON
DASYNOC™ PATENT LITIGATION, PAVING WAY FOR EARLY MARKET LAUNCH
    * SETTLEMENT CLEARS ALL PENDING CLAIMS, PAVING WAY FOR
XSPRAY TO
INTRODUCE DASYNOCTM TO MARKET ON SEPTEMBER 1, 2024, PENDING
FINAL FDA APPROVAL
    * LAUNCH MAY OCCUR EARLIER UNDER CERTAIN CIRCUMSTANCES
    * CONTESTED PATENTS AND THEIR ASSOCIATED REGULATORY
EXCLUSIVITIES
EXPIRE ON SEPTEMBER 28, 2026
    * PARTIES WILL PROCEED TO FILE A DISMISSAL WITH UNITED
STATES
DISTRICT COURT FOR DISTRICT OF NEW JERSEY
    * ELIMINATES NEED FOR ANY ADDITIONAL LITIGATION ON THIS
MATTER

Source text for Eikon:  ID:nMFN1ScJfg 
Further company coverage:  XSPRAY.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))